Sharekhan

Concord Biotech Ltd

Fri 29/08/2025,15:55:35 | NSE : CONCORDBIO

₹ 1681.70-14.00 (-0.83%)

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

Open

₹ 1694.00

Previous Close

₹ 1695.70

Volume

49952

Mkt Cap ( Rs. Cr)

₹17593.31

High

₹ 1717.90

Low

₹ 1675.80

52 Week High

₹ 2664.00

52 Week Low

₹ 1345.00

Book Value Per Share

₹ 152.02

Dividend Yield

0.63

Face Value

₹ 1.00

What’s Your Call?

Collective community sentiment on Concord Biotech Ltd

Your Vote -

Buy

20.00%

Hold

20.00%

Sell

60.00%

20.00%

5 users have voted

Market Depth

How many stocks are available to buy or sell and at what prices.

Buy Order Quantity

NaN%

Sell Order Quantity

NaN%

Bid Price

Qty

0.00

0

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

0

Bid Price

Qty

0.00

0

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

0

Option Chain

Analyzes market sentiment, predicts Concord Biotech Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Concord Biotech Ltd. - General Updates

    21 Aug 2025, 2:15PM Concord Biotech Limited has informed the Exchange about General Updates- Successful Completion Of EU GMP Inspection
  • Concord Biotech Ltd. - Successful Completion Of EU GMP Inspection

    21 Aug 2025, 2:13PM Intimation of successful completion of European Union Good Manufacturing Practices (EU GMP) inspection at our API facility in Limbassi
  • Concord Biotech Ltd. - Analysts/Institutional Investor Meet/Con. Call Updates

    18 Aug 2025, 6:17PM Concord Biotech Limited has informed the Exchange about Transcript
  • Concord Biotech Ltd. - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

    18 Aug 2025, 6:15PM Transcript of Q1FY26 Earning call held on August 11, 2025
  • Concord Biotech Ltd. - Copy of Newspaper Publication

    14 Aug 2025, 11:57AM Concord Biotech Limited has informed the Exchange about Copy of Newspaper Publication for 40th Annual General meeting Notice
  • Concord Biotech Ltd. - Shareholders meeting

    13 Aug 2025, 11:44AM Concord Biotech Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 09, 2025
  • Concord Biotech Ltd. - Business Responsibility and Sustainability Reporting (BRSR)

    13 Aug 2025, 2:41PM Enclosed herewith BRSR for FY 2024-2025
  • Concord Biotech Ltd. - Reg. 34 (1) Annual Report.

    13 Aug 2025, 11:38AM Annual report- Disclosure under Regulation 34 of SEBI(LODR) Regulation, 2015
  • Concord Biotech Ltd. - Intimation Of 40Th Annual General Meeting Notice

    13 Aug 2025, 11:31AM 40th Annual general Meeting to be held on 9th September, 2025 at 4:00 PM through OAVM
  • Concord Biotech Ltd. - Copy of Newspaper Publication

    12 Aug 2025, 2:46PM Concord Biotech Limited has informed the Exchange about Copy of Newspaper Publication for 40th Annual General Meeting, Record date for Dividend and E
  • Concord Biotech Ltd. has declared 1070% Final dividend for the financial year March 2025

    12 Aug 2025, 3:01PM Concord Biotech Ltd. on Thursday, 29 May 2025, has announced Final dividend of 1070 percent on Equity Share, to its shareholders holding shares on the
  • Concord Biotech Ltd. - Analysts/Institutional Investor Meet/Con. Call Updates

    11 Aug 2025, 6:35PM Concord Biotech Limited has informed the Exchange about Link of Recording
  • Concord Biotech Ltd. - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

    11 Aug 2025, 6:32PM Q1FY26 Earnings Call Audio
  • Concord Biotech Ltd. - Investor Presentation

    10 Aug 2025, 12:47PM Concord Biotech Limited has informed the Exchange about Investor Presentation
  • Concord Biotech Ltd. - Copy of Newspaper Publication

    10 Aug 2025, 10:20AM Concord Biotech Limited has informed the Exchange about Copy of Newspaper Publication
  • Concord Biotech Ltd. - Announcement under Regulation 30 (LODR)-Investor Presentation

    10 Aug 2025, 12:45PM Investor Presentation on Financial Results for the Q1 FY25-26
  • Concord Biotech Ltd. - Financial Results Q1 FY 2025-2026

    8 Aug 2025, 5:16PM Financial Results Q1 FY 2025-2026
  • Concord Biotech Q1 net profit down 26.91% at Rs 42.57 cr

    8 Aug 2025, 5:10PM The company reported standalone net profit of Rs 42.57 crore for the quarter ended June 30, 2025 as compared to Rs 58.24 crore in the same period last
  • Concord Biotech Ltd. - Record Date

    8 Aug 2025, 4:56PM Concord Biotech Limited has informed the Exchange that Record date for the purpose of Dividend is 03-Sep-2025.
  • Concord Biotech Ltd. - Outcome of Board Meeting

    8 Aug 2025, 4:54PM Concord Biotech Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
  • Concord Biotech Ltd. - Record Date

    8 Aug 2025, 4:47PM Record date for final dividend
  • Concord Biotech Ltd. - Board Meeting Outcome for Outcome Of Board Meeting

    8 Aug 2025, 4:44PM Outcome of Board Meeting held today , Friday, August 08, 2025- Unaudited Financial Results for the First quarter ended on June 30, 2025
  • Concord Biotech Ltd. - Analysts/Institutional Investor Meet/Con. Call Updates

    5 Aug 2025, 9:53AM Concord Biotech Limited has informed the Exchange about Schedule of meet
  • Concord Biotech Ltd. - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    5 Aug 2025, 9:49AM Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Company has arranged Earnings Call with Inv
  • Concord Biotech Ltd. - Board Meeting Intimation for Approval Of Standalone And Consolidated Unaudited Financial Results For T

    4 Aug 2025, 9:43AM Concord Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/08/2025 ,inter alia, to consider and
  • Concord Biotech Ltd. - General Updates

    26 Jul 2025, 9:53AM Successful Completion Of Russian GMP Inspection
  • Concord Biotech Ltd. - Successful Completion Of Russian GMP Inspection

    26 Jul 2025, 9:48AM Intimation of successful completion of Russian GMP inspection at our API Facility in Dholka
  • Concord Biotech Ltd. - Updates

    22 Jul 2025, 6:57PM Concord Biotech Limited has informed the Exchange regarding 'Acquisition'.
  • Concord Biotech Ltd. - Announcement under Regulation 30 (LODR)-Acquisition

    22 Jul 2025, 6:53PM We are pleased to announce Incorporation of Concord's Wholly owned Subsidiary company, namely, Concord Lifegen Limited
  • Concord Biotech Ltd. has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2025

    19 Jul 2025, 7:01AM As of June 2025, 44.08% is owned by Indian Promoters and 55.92% by Public. <p align=justify> Institutional holds 17.95% (Insurance Companies 3.41%) an
  • Concord Biotech Ltd. - Updates

    18 Jul 2025, 1:09PM Concord Biotech Limited has informed the Exchange regarding ' Successful Completion Of EU GMP Inspection'.
  • Concord Biotech Ltd. - Successful Completion Of EU GMP Inspection

    18 Jul 2025, 1:07PM Intimation of completion of European Union Good Manufacturing Practices (EU GMP) Inspection at our API Facility in Dholka
  • Concord Biotech Ltd. - Certificate under SEBI (Depositories and Participants) Regulations, 2018

    8 Jul 2025, 9:28AM Enclosed herewith the certificate under Regulation 74(5) of the SEBI(DP) Regulations,2018 for the quarter ended 30.06.2025
  • Concord Biotech Ltd. - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    8 Jul 2025, 9:24AM Enclosed herewith the certificate under Regulation 74(5) of the SEBI(DP) Regulations,2018 for the quarter ended 30.06.2025
  • Concord Biotech Ltd. - Acquisition-XBRL

    3 Jul 2025, 9:56AM Concord Biotech Limited has informed the Exchange regarding Acquisition
  • Concord Biotech Ltd. - General Updates

    2 Jul 2025, 10:29AM Concord Biotech Limited has made Investment of USD 1500 in Stellon Biotech Inc.
  • Concord Biotech Ltd. - Announcement under Regulation 30 (LODR)-Acquisition

    2 Jul 2025, 10:23AM Concord Biotech Limited has made Investment of USD 1500 in Stellon Biotech Inc.
  • Concord Biotech Ltd. - Trading Window-XBRL

    26 Jun 2025, 9:32AM Concord biotech limited has informed the Exchange about Closure of Trading Window
  • Concord Biotech Ltd. - Trading Window

    25 Jun 2025, 3:01PM Concord Biotech Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations,
  • Concord Biotech Ltd. - General Updates

    24 Jun 2025, 1:44PM Concord Biotech Limited has informed the Exchange about Concord Biotech limited receives Establishment Inspection Report (EIR) for it''s API facility
  • Concord Biotech Ltd. - Update On The USFDA Inspection At The Company's API Facility At Dholka

    24 Jun 2025, 1:40PM Concord Biotech limited receives Establishment Inspection Report (EIR) for it's API facility at Dholka
  • Concord Biotech Ltd. - Update On The USFDA Inspection At The Company's API Facility At Dholka

    24 Jun 2025, 1:40PM Concord Biotech limited receives Establishment Inspection Report (EIR) for it's API facility at Dholka
  • Concord Biotech Ltd. - General Updates

    2 Jun 2025, 5:52PM Concord Biotech Limited has informed the Exchange about General Updates-Disclosure under Regulation 30(5) of the SEBI (Listing Obligations and Disclos
  • Concord Biotech Ltd. - Analysts/Institutional Investor Meet/Con. Call Updates

    2 Jun 2025, 5:42PM Concord Biotech Limited has informed the Exchange about Schedule of meet
  • Concord Biotech Ltd. - Analysts/Institutional Investor Meet/Con. Call Updates

    2 Jun 2025, 5:40PM Concord Biotech Limited has informed the Exchange about Schedule of meet
  • Concord Biotech Ltd. - Intimation Pursuant To Regulation 30(5) Of The Securities And Exchange Board Of India (Listing Obligat

    2 Jun 2025, 5:58PM Disclosure under Regulation 30(5) of SEBI (LODR) Regulations,2015, Authorization for determining Materiality of Events and Information.
  • Concord Biotech Ltd. - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    2 Jun 2025, 5:37PM Intimation of Schedule of Analyst / Institutional Investor meetings under the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015
  • Concord Biotech Ltd. - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    2 Jun 2025, 5:32PM Intimation of Schedule of Analyst / Institutional Investor meetings under the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015
  • Concord Biotech Ltd. - Copy of Newspaper Publication

    31 May 2025, 2:03PM Concord Biotech Limited has informed the Exchange about Copy of Newspaper Publication
  • Concord Biotech gets USFDA nod for multiple sclerosis treatment

    9 Apr 2025 , 11:46AM Concord Biotech secures Abbreviated New Drug Application (ANDA) approval to Market Teriflunomide Tablets, 7 mg and 14 mg, in the US
  • Concord Biotech

    9 Apr 2025 , 9:57AM The company received approval from the US FDA for marketing 7 mg and 14 mg Teriflunomide Tablets. Teriflunomide Tablets are used for treating patients with relapsing forms of multiple sclerosis. Positive

Key fundamentals

Evaluate the intrinsic value of Concord Biotech Ltd stock 

Name March-25 March-24 March-23 March-22 March-21
Assets 1813.0273 1531.4819 1323.216 1167.7458 1061.0202
Liabilities 1813.0273 1531.4819 1323.216 1167.7458 1061.0202
Equity 10.4616 10.4616 10.4616 9.5106 9.5106
Gross Profit 506.3315 431.5571 343.2875 273.275 327.1095
Net Profit 372.9644 304.7319 238.1264 178.5678 235.3348
Cash From Operating Activities 244.5169 265.4671 246.0018 207.4734 166.8129
NPM(%) 31.07 29.96 27.91 25.04 38.17
Revenue 1200.0869 1016.9392 853.1682 712.9335 616.4044
Expenses 693.7554 585.3821 509.8807 439.6585 289.2949
ROE(%) 23.45 19.16 14.97 11.22 14.79

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day
03 Sep 2025 10.7 1070 0.64 1666.9
21 Jun 2024 8.75 875 0.64 1459.2

Peers

Other companies within the same industry or sector that are comparable to Concord Biotech Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 801.40 0.71 72.66 959.55 301.39 0.62
Lotus Eye Hospital and Institute Ltd 116.84 6.98 376.90 3496.48 3.55 0.00
Vaishali Pharma Ltd 12.24 -0.81 408.00 1802.22 3.13 0.00
Astec Lifesciences Ltd 872.70 1.80 0.00 3297.26 -604.77 0.00

Company Info

The Company was originally incorporated as `Servomed Pharmaceuticals Private Limited' ("Servomed") atAhmedabad, Gujarat as a private limited company under the Companies Act, 1956, pursuant to a certificate of incorporation dated November 23, 1984, issued by the Registrar of Companies, Gujarat, at Ahmedabad ("RoC"). Servomed was authorized to carry out business of manufacturing, producing, refining, importing, exporting, dealing, distributing, wholesaling, retailing etc. of drugs, medicines, cosmetics, baby food, pharmaceuticals, antibiotics and similar or allied products. At the time of its incorporation, Servomed had three directors, namely, Surendra Shah, Madhukant Shah and Indravadan Shah.An application dated June 24, 1985 was filed for undertaking the change in the name of the company to `Concord Pharmaceuticals Private Limited' as the name `Concord' was capable of being easily pronounced and popularized in the pharmaceuticals industry, pursuant to which a revised certificate of incorporation dated September 24, 1985 was issued by the RoC. Subsequently, with effect from December 26, 1986, Concord Pharmaceuticals Private Limited deemed to have become a public company pursuant to Section 43A of Companies Act, 1956. Thereafter, the name of the Company was changed to `Concord Biotech Limited' as the new management of the Company decided to use the available plant and machinery for biotechnology products, and a fresh certificate of incorporation dated February 16, 2001 was issued by the RoC. Subsequently, the Company became a public company from a deemed public company and a fresh certificate of incorporation dated November 7, 2001 was issued by the RoC.Major Events and Milestones in the History of the Company1984- Incorporation of Servomed Pharmaceuticals Private Limited"1985- Change in the name to "Concord Pharmaceuticals Private Limited"1986- Conversion to a deemed public company pursuant to Section 43A of Companies Act, 19562000- Acquisition of the Company by Mr. Sudhir Vaid, one of the Promoters.2001- Renaming of the Company to "Concord Biotech Limited".2002- Expansion of production capacity of enzymes.2003- Certification of the facility at Dholka for commissioning and commencement of production of various enzymes by technical consultants.2004- Investment by Rakesh Jhunjhunwala and Rekha Jhunjhunwala in the Company.2005- First USFDA inspection and classification of the API facility as acceptable.2008- Second USFDA inspection and classification of the API facility as acceptable.2010- Received drug master file registration certificate for tacrolimus hydrate from Pharmaceuticals and Medical Devices Agency, Japan.2011- First EU GMP inspection of the manufacturing facility by Government of Upper BavariaCentral Medicines Control Bavaria (GMP/GCP).- Initiated CRAMs services in areas of new chemical entity ("NCE") or Generic APIs.2012- Received original drug substance registration certificate for mycophenolate mofetil from Pharmaceuticals and Medical Devices Agency, Japan.2013- Third USFDA inspection and classification of the API facility as acceptable.2014- Received certificate of drug substance registry for Ciclosporin JP from Pharmaceuticals and Medical Devices Agency, Japan.2015- Fourth USFDA inspection of the Dholka facility and conclusion of inspection as `closed'.- Second EU GMP inspection of the manufacturing facility.- Received accreditation certificate of foreign drug manufacturing for non-sterile drugs from Minister of Health, Labthe and Welfare of Japan.2016- Established a facility at Valthera, Gujarat.- Recognition of the in-house R&D facility located at Valthera by Ministry of Science and Technology, Government of India.- Investment from Helix Investment Holdings Pte. Limited.2017- First USFDA inspection at the Valthera facility and receipt of establishment inspection report.2018- Fifth USFDA inspection and received `no action indicated' classification for the facility located at Dholka.- Grant of GMP certification from Food and Drugs Control Administration for Valthera and Dholka units Second USFDA inspection at the facility located in Valthera facility and receipt of establishment inspection report.- Established Joint Venture in Japan pursuant to growing business opportunities in Japan.2019- Received two ANDA approvals.- Expansion of the company's business in critical care segment in India.- Commencement of marketing of Mycophenolate Mofetil Capsules USP 250 mg.2020- Board of the Company permitted the layout plan for the proposed injectable manufacturing unit at Valthera facility.- Received two ANDA approvals.- First shipment of Mycophenolate Sodium Tablets, in US market.2021- Commenced operations at second API facility at Limbasi.- Third EU GMP inspection of the manufacturing facility located in Dholka.2023- Completion of the USFDA inspection at the Limbasi facility

The Company was originally incorporated as `Servomed Pharmaceuticals Private Limited' ("Servomed") atAhmedabad, Gujarat as a private limited company under the Companies Act, 1956, pursuant to a certificate of incorporation dated November 23, 1984, issued by the Registrar of Companies, Gujarat, at Ahmedabad ("RoC"). Servomed was authorized to carry out business of manufacturing, producing, refining, importing, exporting, dealing, distributing, wholesaling, retailing etc. of drugs, medicines, cosmetics, baby food, pharmaceuticals, antibiotics and similar or allied products. At the time of its incorporation, Servomed had three directors, namely, Surendra Shah, Madhukant Shah and Indravadan Shah.An application dated June 24, 1985 was filed for undertaking the change in the name of the company to `Concord Pharmaceuticals Private Limited' as the name `Concord' was capable of being easily pronounced and popularized in the pharmaceuticals industry, pursuant to which a revised certificate of incorporation dated September 24, 1985 was issued by the RoC. Subsequently, with effect from December 26, 1986, Concord Pharmaceuticals Private Limited deemed to have become a public company pursuant to Section 43A of Companies Act, 1956. Thereafter, the name of the Company was changed to `Concord Biotech Limited' as the new management of the Company decided to use the available plant and machinery for biotechnology products, and a fresh certificate of incorporation dated February 16, 2001 was issued by the RoC. Subsequently, the Company became a public company from a deemed public company and a fresh certificate of incorporation dated November 7, 2001 was issued by the RoC.Major Events and Milestones in the History of the Company1984- Incorporation of Servomed Pharmaceuticals Private Limited"1985- Change in the name to "Concord Pharmaceuticals Private Limited"1986- Conversion to a deemed public company pursuant to Section 43A of Companies Act, 19562000- Acquisition of the Company by Mr. Sudhir Vaid, one of the Promoters.2001- Renaming of the Company to "Concord Biotech Limited".2002- Expansion of production capacity of enzymes.2003- Certification of the facility at Dholka for commissioning and commencement of production of various enzymes by technical consultants.2004- Investment by Rakesh Jhunjhunwala and Rekha Jhunjhunwala in the Company.2005- First USFDA inspection and classification of the API facility as acceptable.2008- Second USFDA inspection and classification of the API facility as acceptable.2010- Received drug master file registration certificate for tacrolimus hydrate from Pharmaceuticals and Medical Devices Agency, Japan.2011- First EU GMP inspection of the manufacturing facility by Government of Upper BavariaCentral Medicines Control Bavaria (GMP/GCP).- Initiated CRAMs services in areas of new chemical entity ("NCE") or Generic APIs.2012- Received original drug substance registration certificate for mycophenolate mofetil from Pharmaceuticals and Medical Devices Agency, Japan.2013- Third USFDA inspection and classification of the API facility as acceptable.2014- Received certificate of drug substance registry for Ciclosporin JP from Pharmaceuticals and Medical Devices Agency, Japan.2015- Fourth USFDA inspection of the Dholka facility and conclusion of inspection as `closed'.- Second EU GMP inspection of the manufacturing facility.- Received accreditation certificate of foreign drug manufacturing for non-sterile drugs from Minister of Health, Labthe and Welfare of Japan.2016- Established a facility at Valthera, Gujarat.- Recognition of the in-house R&D facility located at Valthera by Ministry of Science and Technology, Government of India.- Investment from Helix Investment Holdings Pte. Limited.2017- First USFDA inspection at the Valthera facility and receipt of establishment inspection report.2018- Fifth USFDA inspection and received `no action indicated' classification for the facility located at Dholka.- Grant of GMP certification from Food and Drugs Control Administration for Valthera and Dholka units Second USFDA inspection at the facility located in Valthera facility and receipt of establishment inspection report.- Established Joint Venture in Japan pursuant to growing business opportunities in Japan.2019- Received two ANDA approvals.- Expansion of the company's business in critical care segment in India.- Commencement of marketing of Mycophenolate Mofetil Capsules USP 250 mg.2020- Board of the Company permitted the layout plan for the proposed injectable manufacturing unit at Valthera facility.- Received two ANDA approvals.- First shipment of Mycophenolate Sodium Tablets, in US market.2021- Commenced operations at second API facility at Limbasi.- Third EU GMP inspection of the manufacturing facility located in Dholka.2023- Completion of the USFDA inspection at the Limbasi facility

Read More

Parent Organisation

Concord Biotech Ltd.

Founded

23/11/1984

Managing Director

Mr.Ankur Vaid

NSE Symbol

CONCORDBIOEQ

FAQ

The current price of Concord Biotech Ltd is ₹ 1681.70.

The 52-week high for Concord Biotech Ltd is ₹ 1717.90 and the 52-week low is ₹ 1675.80.

The market capitalization of Concord Biotech Ltd is currently ₹ 17593.31. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.

To buy Concord Biotech Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.

To invest in Concord Biotech Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Concord Biotech Ltd shares.

The CEO of Concord Biotech Ltd is Mr.Ankur Vaid, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.

OPEN FREE* DEMAT ACCOUNT